Natural Products

ChemFaces

Diosbulbin B Datasheet

4th Edition (Revised in July, 2016)

[Product Information]

Name: Diosbulbin B

Catalog No.: CFN98014

Cas No.: 20086-06-0

Purity: > 98%

M.F: $C_{19}H_{20}O_6$

M.W: 344.4



Physical Description: Powder

Synonyms:(2R,3aS,6S,6aS,7R,10R,11aR,11bS)-2-(3-Furanyl)octahydro-11b-methyl-4H-3a,6:7,10-dimethanofuro[2,3-c]oxepino[4,5-e]oxepin-4,8(6H)-dione;

8,12:15,16-Diepoxy-19-nor-13(16),14-clerodadiene-17,6:18,2-diolide.

[Intended Use]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

[Source]

The herbs of *Dioscorea bulbifera.*

[Biological Activity or Inhibitors]

Diosbulbin B (DB), a diterpene lactone isolated from D. bulbifera L., has hepatotoxicity, oral administration of DB for 12 consecutive days can lead to the oxidative stress liver injury in mice;ferulic acid prevents DB-induced liver injury via ameliorating DB-induced liver oxidative stress injury and augments DB-induced anti-tumor activity; Scutellarin(SC) also prevents DB-induced liver injury by attenuating NF-κB-mediated hepatic inflammation and ameliorating liver oxidative stress injury, DB plus SC has significant anti-tumor activity in vivo; indicates that the potential combination of DBo with SC or ferulic acid for the treatment of cancer in clinic.[1,3]

Diosbulbin B has inhibition of gastric cancer cell line SGC-7901 proliferation.[4]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[HPLC Method][5]

Mobile phase: Acetonitrile- 0.1% Glacial acetic acid H2O=40: 60 ;

Flow rate: 1.0 ml/min;

Column temperature: 25 ℃;

The wave length of determination: 210 nm.

[Storage]

2-8℃, Protected from air and light, refrigerate or freeze.

[References]

[1] Ma Y, Niu C, Wang J, *et al. Human & Experimental Toxicology, 2014, 33(7):729-36.*

[2] Wang J M, Sheng Y C, Ji L L, *et al. Journal of Zhejiang Universityence B, 2014, 15(6):540-7.*

[3] Niu C, Sheng Y, Rui Y, *et al. J. Ethnopharmacol., 2015, 164:301-8.*

[4] Zhao J, Cheng S, L i P K. *Medical Research & Education, , 2013,30(3):13-5.*

[5] Hua C B, Ma L N, Shi D H, *et al. Pharmacy and Clinices Chinese Materia Medica, 2013, 4 (2):50-3.*

[Contact]

Address:
S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680
Web: www.chemfaces.com
Tech Support: service@chemfaces.com